A study analyzing the FDA adverse event reporting system (AERS) database found that use of GLP-1-based therapies, specifically exenatide and sitagliptin, was associated with a significantly increased risk of pancreatitis compared to other diabetes treatments. The odds ratio for pancreatitis was 6-fold higher with these drugs. Additionally, pancreatic cancer was more commonly reported in patients taking exenatide or sitagliptin compared to other therapies. Thyroid cancer was also more frequently reported with exenatide, though not with sitagliptin. No significant increase in other cancers was observed. The study raises concerns about the long-term effects of GLP-1-based therapies on pancreatic cancer risk, as pancreatitis is a known risk factor for pancreatic cancer. The findings suggest that these drugs may contribute to the development of pancreatic cancer, although further research is needed to confirm this. The study also highlights the limitations of the AERS database, including potential reporting biases and incomplete data. Despite these limitations, the results indicate that GLP-1-based therapies may have serious unintended side effects, particularly in relation to pancreatitis and cancer. The study emphasizes the need for long-term monitoring of patients treated with these drugs.A study analyzing the FDA adverse event reporting system (AERS) database found that use of GLP-1-based therapies, specifically exenatide and sitagliptin, was associated with a significantly increased risk of pancreatitis compared to other diabetes treatments. The odds ratio for pancreatitis was 6-fold higher with these drugs. Additionally, pancreatic cancer was more commonly reported in patients taking exenatide or sitagliptin compared to other therapies. Thyroid cancer was also more frequently reported with exenatide, though not with sitagliptin. No significant increase in other cancers was observed. The study raises concerns about the long-term effects of GLP-1-based therapies on pancreatic cancer risk, as pancreatitis is a known risk factor for pancreatic cancer. The findings suggest that these drugs may contribute to the development of pancreatic cancer, although further research is needed to confirm this. The study also highlights the limitations of the AERS database, including potential reporting biases and incomplete data. Despite these limitations, the results indicate that GLP-1-based therapies may have serious unintended side effects, particularly in relation to pancreatitis and cancer. The study emphasizes the need for long-term monitoring of patients treated with these drugs.